FDA Approves Tecelra Gene Therapy for Unresectable Synovial Sarcoma
The U.S. Food and Drug Administration (FDA) has granted approval for Tecelra (afamitresgene autoleucel), a groundbreaking gene therapy designed to treat adults with unresectable or metastatic synovial sarcoma. This approval represents a significant advancement in cancer treatment options for patients who have exhausted standard therapies. Synovial Sarcoma: A Rare Challenge Synovial sarcoma is a rare…